Nanomedicine-Driven Drug Delivery Innovations in Breast Cancer Management: Targeting Tumor Heterogeneity and Overcoming Multidrug Resistance

Breast cancer remains the most frequently diagnosed malignancy and the leading cause of cancer-related deaths among women worldwide. According to the Global Cancer Observatory (GLOBOCAN 2024), breast cancer accounted for over 2.3 million new cases and approximately 670,000 deaths globally, reflecting its growing incidence and significant public health burden (Sung et al., 2024). The increasing prevalence in both developed and developing nations is attributed to lifestyle changes, aging populations, genetic predispositions, and delayed diagnosis. Despite advancements in screening and therapeutic strategies, metastatic and recurrent breast cancers continue to pose considerable clinical challenges.

Conventional therapeutic modalities, including chemotherapy and endocrine therapy, remain the cornerstone of breast cancer management; however, their limitations are substantial. Chemotherapeutic drugs often exhibit poor selectivity, resulting in systemic toxicity, suboptimal tumor accumulation, and rapid clearance (Harbeck & Gnant, 2017). Endocrine therapies, while effective for hormone receptor–positive cancers, frequently encounter acquired resistance due to receptor mutations, adaptive signaling pathways, and alterations within the tumor microenvironment (Musgrove & Sutherland, 2021). Collectively, these limitations contribute to therapeutic failure and unfavorable clinical outcomes.

A critical factor undermining treatment success is tumor heterogeneity, which manifests at both intertumoral and intratumoral levels. Breast cancer subtypes exhibit distinct genomic and phenotypic profiles, leading to variable therapeutic responses (Dai et al., 2022). Intratumoral heterogeneity further complicates treatment by fostering diverse cancer cell populations with differential sensitivity to therapy. Cancer stem cells (CSCs), epithelial–mesenchymal transition (EMT) phenotypes, and hypoxia-driven adaptations contribute to heightened resistance and tumor relapse (Prat & Perou, 2023). These variations create a dynamic ecosystem within tumors, limiting the effectiveness of single-agent or non-targeted treatments.

The development of multidrug resistance (MDR) is another major impediment in breast cancer therapy. MDR arises through multiple mechanisms, including the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), which actively efflux chemotherapeutic agents out of cancer cells (Wu et al., 2021). Additional contributors include EMT-driven phenotypic plasticity, activation of pro-survival pathways, epigenetic alterations, and the persistence of CSCs that exhibit intrinsic resistance to cytotoxic agents (Liang et al., 2022). The tumor microenvironment (TME), characterized by hypoxia, immune suppression, and remodeled extracellular matrix components, further enhances drug resistance and supports tumor progression (Junttila & de Sauvage, 2013).

In recent years, nanomedicine has emerged as a transformative platform capable of addressing the limitations of conventional therapies while targeting the complexities of breast cancer biology. Nanocarrier-based drug delivery systems—including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and biomimetic nanocarriers—enhance drug solubility, improve pharmacokinetics, and offer targeted delivery to tumor tissues while minimizing systemic toxicity (Wicki et al., 2015). Their ability to bypass efflux pumps, modulate the TME, and co-deliver multiple therapeutic agents positions nanomedicine as a promising strategy in overcoming MDR and tumor heterogeneity. As precision oncology advances, the integration of intelligent nanocarriers holds substantial potential to reshape breast cancer management and improve long-term patient outcomes.

2. Tumor Heterogeneity in Breast Cancer

Tumor heterogeneity represents one of the primary challenges in breast cancer management, significantly influencing therapeutic outcomes and contributing to drug resistance. It encompasses variations between tumors of different patients (intertumoral heterogeneity) as well as within individual tumors (intratumoral heterogeneity). The dynamic nature of the tumor microenvironment (TME) further shapes these differences, promoting survival pathways and diminishing treatment responses (Bianchini et al., 2022).

2.1 Intertumoral Heterogeneity

Intertumoral heterogeneity refers to variations between tumors among different patients, largely attributed to molecular subtyping, genetic makeup, and phenotypic diversity. Breast cancer is classified into major molecular subtypes—Luminal A, Luminal B, HER2-enriched, and Triple-Negative/Basal-like—each differing in aggressiveness, therapeutic targets, and prognosis (Perou et al., 2020).

Luminal A tumors typically express estrogen receptors with low proliferation rates, while Luminal B tumors exhibit higher Ki-67 levels and variable HER2 expression. HER2-positive tumors are characterized by amplification of the ERBB2 gene and respond to HER2-targeted therapies. In contrast, Triple-Negative Breast Cancer (TNBC) lacks ER, PR, and HER2 expression, presenting substantial therapeutic challenges and high recurrence rates (Yin et al., 2021).

Genetic and phenotypic diversity among these subtypes drives differential therapeutic sensitivity. Mutations in PIK3CA, BRCA1/2, TP53, and variations in signaling pathways such as PI3K/Akt, MAPK, and immune-regulatory networks contribute to variability in treatment response (Razavi et al., 2019). This diversity underscores the need for subtype-specific therapeutic strategies.

2.2 Intratumoral Heterogeneity

Intratumoral heterogeneity encompasses differences within a single tumor mass. This heterogeneity arises from clonal evolution, whereby tumor cells acquire mutations over time, generating diverse subpopulations with distinct phenotypes and drug sensitivities (McGranahan & Swanton, 2017). Spatial heterogeneity further complicates treatment, as various regions of the tumor may exhibit differential hypoxia levels, proliferation rates, and receptor expression.

Cancer stem cells (CSCs) significantly contribute to intratumoral heterogeneity. CSCs exhibit self-renewal capabilities, pluripotency, and increased resistance to chemotherapy and radiotherapy (Batlle & Clevers, 2017). These cells often survive conventional treatments and repopulate tumors, leading to recurrence and metastasis. CSC-associated markers such as CD44?/CD24?, ALDH1, and SOX2 correlate with aggressive phenotypes and poor prognosis (Liu et al., 2020).

2.3 Tumor Microenvironment (TME)

The TME plays a critical role in shaping breast cancer heterogeneity. It comprises stromal components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM), blood vessels, and signaling molecules. TME-induced hypoxia triggers stabilization of hypoxia-inducible factors (HIFs), leading to angiogenesis, metabolic reprogramming, and resistance to chemotherapy (Vaupel & Mayer, 2021).

ECM remodeling alters tissue stiffness and enhances invasive potential, while CAFs secrete cytokines (e.g., TGF-β, IL-6) that promote EMT and immune evasion. Immune cells, including tumor-associated macrophages (TAMs), regulatory T-cells, and myeloid-derived suppressor cells (MDSCs), suppress antitumor immunity and support tumor progression (Kumari et al., 2022).

The cumulative influence of TME-driven cues fosters a drug-resistant phenotype, diminishing therapeutic efficacy and promoting multidrug resistance (Pitt et al., 2016). Understanding these interactions is essential for designing targeted nanomedicine approaches capable of overcoming TME-associated barriers.

Table 1. Major Contributors to Tumor Heterogeneity in Breast Cancer

3. Mechanisms Underlying Multidrug Resistance (MDR)

Multidrug resistance (MDR) presents a significant barrier to effective breast cancer treatment, leading to therapeutic failure and disease recurrence. MDR arises from a combination of cellular, molecular, and microenvironmental factors that collectively reduce the efficacy of chemotherapeutic and targeted agents. Key contributors include drug efflux transporters, tumor microenvironment–mediated adaptations, cancer stem cells, genetic/epigenetic modifications, and epithelial–mesenchymal transition (EMT) processes. Understanding these mechanisms is essential for the development of advanced strategies such as nanomedicine to overcome therapy resistance (Wu et al., 2021).

3.1 Drug Efflux Pumps

The overexpression of ATP-binding cassette (ABC) transporters is one of the most widely studied mechanisms of MDR. P-glycoprotein (P-gp; ABCB1) actively effluxes chemotherapeutic agents including doxorubicin, paclitaxel, and vincristine, significantly reducing intracellular drug accumulation (Gottesman et al., 2016). Other transporters such as Multidrug Resistance Protein 1 (MRP1) and Breast Cancer Resistance Protein (BCRP; ABCG2) contribute to similar efflux-driven resistance patterns (Robey et al., 2021). Overexpression of these transporters is frequently associated with poor prognosis and resistance to both conventional chemotherapy and targeted therapy.

3.2 Tumor Microenvironment-Induced Resistance

The tumor microenvironment (TME) plays a crucial role in promoting MDR by altering metabolic pathways, immune responses, and cellular phenotypes. Hypoxia, a hallmark of the TME, stabilizes hypoxia-inducible factor-1α (HIF-1α), which activates transcription of genes associated with glycolysis, angiogenesis, and survival (Vaupel & Mayer, 2021). Hypoxia-driven pathways also upregulate P-gp and promote quiescence, enabling tumor cells to escape drug-induced apoptosis (Harris, 2022). In addition, cancer-associated fibroblasts (CAFs), immune suppressive cells, and extracellular matrix (ECM) components create a protective niche that inhibits drug penetration and enhances cell survival.

3.3 Cancer Stem Cell-Mediated Resistance

Cancer stem cells (CSCs) are a subpopulation with self-renewal capacity and inherent resistance to chemotherapeutic agents. CSCs overexpress efflux pumps (e.g., P-gp, BCRP), possess heightened DNA repair capabilities, and exhibit slow-cycling behavior, rendering them less susceptible to cytotoxic drugs (Batlle & Clevers, 2017). CSC markers such as CD44?/CD24?, ALDH1, and SOX2 correlate with metastatic potential and recurrence (Liu et al., 2020). Their persistence following therapy contributes to tumor repopulation and resistance.

3.4 Genetic and Epigenetic Alterations

Genetic mutations, gene amplifications, and chromosomal rearrangements significantly influence drug resistance. Alterations in TP53, BRCA1, PIK3CA, and ERBB2 can modify drug responses by activating pro-survival signaling pathways (Razavi et al., 2019). Epigenetic changes—such as DNA methylation, histone modification, and non-coding RNA dysregulation—further contribute to MDR by altering gene expression without modifying DNA sequences (Jones et al., 2016). These modifications can silence tumor suppressor genes or activate oncogenic pathways that support drug resistance.

3.5 Epithelial–Mesenchymal Transition (EMT)

EMT is a phenotypic transition where epithelial cancer cells acquire mesenchymal traits, enabling enhanced motility, invasiveness, and resistance to apoptosis. EMT activation is driven by transcription factors such as Snail, Slug, Twist, and ZEB1/2, which downregulate epithelial markers (E-cadherin) and upregulate mesenchymal markers (vimentin, N-cadherin) (Dongre & Weinberg, 2019). EMT also promotes stem-cell–like features and increases resistance to both chemotherapy and targeted therapies, partly by interacting with TME cues and hypoxia-mediated signaling.

Table 2. Summary of Key Mechanisms Contributing to Multidrug Resistance in Breast Cancer

4. Nanomedicine Approaches in Breast Cancer Management

Nanomedicine has emerged as a transformative strategy for addressing the limitations of conventional breast cancer therapies. Nanocarriers—including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and biomimetic systems—provide enhanced pharmacokinetics, targeted drug delivery, and reduced systemic toxicity. Their nanoscale properties enable improved tumor accumulation, the ability to modulate the tumor microenvironment, and mechanisms to bypass multidrug resistance (MDR). Collectively, these advantages position nanomedicine as a promising platform in precision oncology (Wicki et al., 2015).

4.1 Improved Pharmacokinetics and Biodistribution

Nanocarriers significantly enhance the pharmacokinetic profile of anticancer drugs by increasing circulation time, improving solubility, and protecting drugs from premature degradation. Polyethylene glycol (PEG)–coated nanoparticles resist opsonization, enabling prolonged systemic circulation (Kumar et al., 2020). Their optimized size (typically 10–200 nm) facilitates preferential accumulation in tumor tissue via the enhanced permeability and retention (EPR) effect, thereby improving biodistribution (Blanco et al., 2015). This controlled distribution reduces systemic exposure and enhances therapeutic index.

4.2 Targeted Delivery to Tumor Tissue

Nanocarriers enable both passive and active targeting strategies.

• Passive targeting exploits leaky tumor vasculature and poor lymphatic drainage, allowing nanoparticles to accumulate at tumor sites.
• Active targeting involves ligand modification using antibodies, peptides, aptamers, or small molecules that bind to overexpressed receptors such as HER2, EGFR, and folate receptors (Mohanraj & Chen, 2022).

Active targeting enhances internalization and minimizes off-target drug distribution. For example, trastuzumab-conjugated nanoparticles selectively target HER2-positive breast cancer cells, significantly improving therapeutic efficacy and reducing toxicity (Jin et al., 2021).

4.3 Reduced Toxicity to Normal Cells

Conventional chemotherapeutics often harm rapidly dividing normal cells, causing severe adverse effects. Nanocarriers encapsulate cytotoxic agents, preventing premature release and reducing systemic toxicity (Hare et al., 2017). Controlled and site-specific drug release ensures that the majority of the payload is delivered directly into tumor tissues.

Liposomal formulations such as liposomal doxorubicin demonstrate reduced cardiotoxicity and myelosuppression while maintaining strong antitumor activity (Barenholz, 2012). This reduction in collateral damage markedly improves patient tolerability and quality of life.

4.4 Ability to Bypass Efflux Pumps and MDR Pathways

Nanocarriers offer unique mechanisms to overcome multidrug resistance. Their ability to enter cancer cells through endocytosis reduces reliance on diffusion—a process heavily affected by efflux transporters like P-gp, MRP1, and BCRP (Wu et al., 2021). Moreover, nanoparticles can:

• Shield chemotherapeutic molecules from recognition by efflux pumps.
• Deliver efflux pump inhibitors (e.g., verapamil, tariquidar) in combination formulations.
• Target cancer stem cells (CSCs) using ligand-based approaches.
• Deliver siRNA/miRNA to silence MDR-related genes such as ABCB1 (Chen et al., 2018).

Polymeric nanoparticles, mesoporous silica nanoparticles, and exosome-based carriers have shown strong potential in reversing MDR by modifying intracellular drug distribution and TME dynamics.

Table 3. Key Advantages of Nanomedicine in Overcoming Breast Cancer Treatment Barriers

5. Types of Nanocarriers in Breast Cancer Therapy

Nanocarrier-based drug delivery platforms have emerged as highly promising tools for improving therapeutic efficacy, reducing systemic toxicity, and overcoming the biological barriers associated with breast cancer treatment. These nanosystems differ in their composition, physicochemical characteristics, and targeting capabilities, enabling tailored strategies to address tumor heterogeneity and multidrug resistance (MDR) (Peer et al., 2020; Wicki et al., 2015).

5.1 Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate hydrophilic or hydrophobic drugs. Clinically approved liposomal formulations—such as Doxil® and Myocet®—have demonstrated reduced cardiotoxicity and improved circulation time for anthracycline drugs in breast cancer therapy (Barenholz, 2012).

PEGylation prolongs circulation by preventing opsonization, while active targeting using ligands (e.g., folate, antibodies, peptides) enhances receptor-mediated uptake by tumor cells (Chang et al., 2020).

5.2 Polymeric Nanoparticles

Polymeric nanoparticles composed of biodegradable materials such as PLA, PLGA, and PEG-PLA offer controlled and sustained drug release (Kumari et al., 2010). Their tunable physicochemical properties allow optimization of drug loading, stability, and biological interactions.

Targeted polymeric nanoparticles delivering drugs such as paclitaxel or doxorubicin have shown enhanced anticancer activity and reduced off-target toxicity in breast cancer models (Danhier, 2016).

5.3 Metallic & Inorganic Nanoparticles

Metallic and inorganic nanocarriers—such as gold nanoparticles, mesoporous silica nanoparticles, and iron oxide nanoparticles—provide unique optical, magnetic, or structural features (Jain et al., 2012).

• Gold nanoparticles enable photothermal therapy (PTT), enhancing tumor ablation.
• Mesoporous silica nanoparticles support high drug loading and stimuli-responsive release.
• Iron oxide nanoparticles facilitate imaging-guided therapy and magnetic targeting.

These multifunctional systems integrate diagnosis and therapy (“theranostics”), improving precision treatment.

5.4 Dendrimers

Dendrimers are hyperbranched nanostructures possessing a multivalent surface that allows simultaneous drug conjugation, targeting ligands, and imaging agents (Kannan et al., 2014).

PAMAM dendrimers are widely studied for doxorubicin and siRNA delivery. Their nanoscale precision enables enhanced tumor penetration and intracellular uptake, contributing to MDR reversal.

5.5 Nanomicelles

Nanomicelles formed by amphiphilic block copolymers improve the solubility of hydrophobic chemotherapeutics such as paclitaxel or curcumin (Garg et al., 2020).

Their small size (<100 nm) enhances tumor penetration, while the hydrophobic core allows high drug loading. Stimuli-responsive micelles further improve targeted release at the tumor site.

5.6 Biomimetic Nanocarriers

Biomimetic nanocarriers use cell membrane coatings derived from RBCs, leukocytes, cancer cells, or platelets to evade immune detection (Fang et al., 2018).

Examples include:

• RBC-coated nanoparticles for prolonged circulation.
• Leukocyte-coated particles for inflammation-associated tumor targeting.
• Cancer cell membrane-coated nanocarriers for homotypic targeting and antigen presentation.

These systems overcome immunological barriers and enhance tumor accumulation.

5.7 Exosomes and Extracellular Vesicles

Exosomes act as natural vesicular carriers involved in intercellular communication. Their intrinsic biocompatibility and ability to transport miRNAs, siRNAs, proteins, and drugs make them attractive for breast cancer therapy (Kalluri & LeBleu, 2020).

Engineered exosomes demonstrate promising results in reversing MDR and delivering gene-silencing materials to tumor cells.

5.8 Nanoemulsions and Nanogels

Nanoemulsions improve solubility and stability of poorly water-soluble anticancer agents such as tamoxifen or curcumin (Gupta et al., 2016). Their rapid uptake and enhanced permeability support efficient tumor delivery.

Nanogels—hydrophilic polymeric networks—are capable of swelling and responding to stimuli (pH, temperature), offering controlled drug release and high biocompatibility (Vincent et al., 2017).

Tumor heterogeneity (inter- and intratumoral) demands adaptable, multi-modal therapeutic approaches. Nanomedicine offers modular platforms that can be engineered for subtype specificity, CSC eradication, microenvironment modulation, and spatially heterogeneous drug delivery. The strategies below summarize how nanocarriers are being designed to address each facet of heterogeneity and improve therapeutic outcomes (Peer et al., 2020; Wicki et al., 2015).

6.1 Subtype-Specific Targeting

Rationale. Molecular subtypes (HER2+, hormone-receptor positive, TNBC) express distinct surface markers and signalling dependencies that can be exploited by ligand-guided nanoparticles for selective delivery.

HER2-targeted nanocarriers. Nanoparticles conjugated with anti-HER2 antibodies or HER2-binding peptides (e.g., trastuzumab-functionalized liposomes or polymeric NPs) selectively bind and internalize in HER2-overexpressing cells, increasing intratumoral drug accumulation and reducing off-target toxicity (Jin et al., 2021; Peer et al., 2020).

Hormone-receptor–targeted nanoparticles. For ER/PR+ tumors, nanocarriers bearing ligands for estrogen receptors or transporters (or loaded with endocrine agents in controlled-release matrices) improve local drug exposure and may overcome endocrine resistance when combined with co-delivered pathway inhibitors (Danhier, 2016; Musgrove & Sutherland, 2021).

Strategies for Triple-Negative Breast Cancer (TNBC). TNBC lacks canonical receptors and is highly heterogeneous; solutions include (a) nanoparticles targeting overexpressed integrins or folate receptors, (b) immune-stimulating nanovaccines, and (c) “agnostic” multifunctional nanoparticles that co-deliver chemotherapy + immunomodulators or siRNA against survival pathways—approaches designed to simultaneously address multiple resistance mechanisms in TNBC (Peer et al., 2020; Bianchini et al., 2022).

6.2 Targeting Cancer Stem Cells (CSCs)

Rationale. CSCs are therapy-resistant subpopulations that drive recurrence and metastasis; eliminating CSCs is critical for durable responses.

Nanocarriers delivering CSC inhibitors. Lipid or polymeric nanoparticles can encapsulate CSC-selective agents (e.g., salinomycin) or deliver nucleic acids (siRNA/miRNA) to silence stemness genes (e.g., SOX2, ALDH1)—increasing drug concentration within CSC niches while reducing systemic exposure (Gupta et al., 2009; Chen et al., 2018).

Multifunctional nanoparticles inhibiting CSC niches. Combining CSC inhibitors with agents that remodel the niche (e.g., TGF-β inhibitors, anti-hypoxia payloads) in a single carrier, or using surface ligands that recognize CSC markers (CD44, CD133), increases selectivity and reduces the probability of CSC-driven relapse (Batlle & Clevers, 2017; Liu et al., 2020).

6.3 Modulating the Tumor Microenvironment (TME)

Rationale. The TME (hypoxia, CAFs, ECM, immune suppression) fosters heterogeneity and drug resistance; nanomedicine can actively reprogram or penetrate the TME.

Nanoparticles targeting hypoxia or CAFs. Hypoxia-responsive nanocarriers release payloads under low-oxygen conditions (HIF-responsive linkers or pH/enzymatic triggers), delivering cytotoxics or HIF inhibitors selectively to hypoxic regions (Vaupel & Mayer, 2021). Nanoparticles that deliver CAF-modulating agents (e.g., TGF-β inhibitors, CAF-depleting siRNA) can reduce stromal barriers and improve drug penetration (Kumari et al., 2022).

Immuno-nanomedicine for TME reprogramming. Nanovaccines, nanoparticle delivery of immune checkpoint inhibitors, or carriers that co-deliver adjuvants plus tumor antigens can reverse immune suppression and convert “cold” tumors into “hot” ones, enhancing both direct cytotoxicity and subsequent immune surveillance (Peer et al., 2020; Kalluri & LeBleu, 2020).

6.4 Spatial Heterogeneity Solutions

Rationale. Within a single lesion, regions differ in vasculature, cell phenotype, and drug accessibility; spatially adaptive strategies are required.

Multifunctional and stimuli-responsive nanocarriers. Smart carriers that respond to pH, enzymes, redox status, or external triggers (ultrasound, light, magnetic field) enable spatiotemporally controlled release only in microregions with permissive cues—improving local potency while limiting systemic toxicity (Danhier, 2016; Wicki et al., 2015).

Multi-drug loaded nanoparticles. Co-encapsulation of synergistic drugs (e.g., cytotoxic + MDR inhibitor, chemotherapy + immunomodulator) in a single nanoparticle enforces coordinated delivery to heterogeneous cell populations, reducing the chance that subclones escape therapy (Wu et al., 2021). Layered or compartmentalized carriers can release different agents sequentially to target proliferating cells, CSCs, and the stroma in a programmed manner.

MDR in breast cancer arises from efflux pump overexpression, genetic alterations, cancer stem cell (CSC) survival, EMT activation, and the protective tumor microenvironment. Nanomedicine platforms offer versatile molecular and biophysical strategies to overcome these resistance mechanisms by enhancing intracellular drug retention, inhibiting resistance pathways, and enabling multimodal therapy (Wu et al., 2021; Peer et al., 2020).

7.1 Inhibition of Efflux Pumps

P-gp inhibitors co-delivered in nanoparticles

Nanocarriers allow co-encapsulation of chemotherapeutics with P-glycoprotein (P-gp) inhibitors such as verapamil, tariquidar, or curcumin. Co-delivery maximizes intracellular drug concentration by localizing inhibitors at the same cellular sites where efflux pumps act (Patil et al., 2020). This reduces the toxicity typically associated with systemic P-gp inhibitors.

siRNA/miRNA-based suppression of MDR genes

Polymeric nanoparticles, liposomes, and exosomes effectively deliver siRNA or miRNA targeting MDR genes (ABCB1, ABCC1, BCRP) (Chen et al., 2018). Silencing efflux pump production reduces resistance and sensitizes breast cancer cells to agents such as doxorubicin and paclitaxel.

7.2 Nanocarriers Bypassing Efflux Mechanisms

Nanoparticles are internalized through endocytic pathways (clathrin/caveolae-mediated uptake), effectively bypassing plasma membrane efflux pumps (Sarkar et al., 2015). Once inside endosomes, nanocarriers release drugs directly into the cytoplasm, overwhelming MDR mechanisms and increasing effective intracellular drug concentrations.

7.3 Combination Nanotherapies

Co-delivery of chemotherapy + gene therapy

Nanoparticles can simultaneously carry:

• chemotherapeutic drugs (e.g., DOX, PTX),
• siRNA/miRNA targeting survival or resistance pathways.

This provides synergistic suppression of MDR genes and cytotoxic killing of tumor cells (Wu et al., 2021).

Co-delivery of immunotherapy + chemotherapy

Nanocarriers formulated with checkpoint inhibitors (e.g., anti-PD-L1 peptides), immunostimulatory adjuvants, and cytotoxic drugs enhance immune activation while cytoreducing tumor mass—effective especially in immunosuppressed TNBC environments (Kalluri & LeBleu, 2020).

Photothermal/photodynamic therapy + drugs

Gold nanorods, graphene oxide, and porphyrin-loaded nanoparticles enhance localized heating or ROS generation upon NIR irradiation, increasing drug uptake, damaging MDR cell membranes, and sensitizing resistant cells (Jain et al., 2012).

7.4 Hyperthermia & Photothermal Nanoparticles

Gold nanoparticles and iron oxide nanoparticles serve as potent hyperthermia agents. Under near-infrared light or alternating magnetic fields, they elevate tumor temperature to 42–45°C, which:

• increases membrane permeability,
• suppresses P-gp activity,
• enhances chemotherapeutic penetration,
• triggers apoptosis in resistant cell populations (Huang et al., 2010).

This thermal effect can be combined with drug loading for dual-mode MDR reversal.

7.5 Targeting EMT and Signaling Pathways

EMT contributes to therapy resistance, invasiveness, and stemness. Nanomedicine enables targeted inhibition of EMT-related signaling pathways:

• PI3K/Akt inhibition through nanoparticle-loaded PI3K blockers improves apoptosis in resistant cells.
• NF-κB inhibition using curcumin nanoparticles or siRNA nanocarriers blocks survival signaling and inflammatory feedback loops (Zheng et al., 2020).
• Wnt/β-catenin pathway suppression via dendrimer or polymeric nanoparticles carrying Wnt inhibitors or miR-34a mimics reduces CSC populations and reverses EMT (Liu et al., 2020).

These interventions restore sensitivity to conventional chemotherapy and prevent metastatic progression.

8. Challenges and Limitations in Clinical Translation of Nanomedicine

Nanomedicine has demonstrated remarkable potential in preclinical breast cancer research; however, several scientific, regulatory, and translational barriers continue to limit its widespread clinical adoption.

8.1 Biological and Physiological Barriers

8.1.1 Heterogeneous Tumor Vasculature

The enhanced permeability and retention (EPR) effect varies widely across breast cancer subtypes and patient populations, resulting in inconsistent nanoparticle accumulation (Wilhelm et al., 2016). Poorly perfused tumor regions and dense extracellular matrix can significantly restrict nanocarrier penetration.

8.1.2 Immune System Clearance

Opsonization and phagocytic uptake by the mononuclear phagocyte system (MPS) reduce circulation half-life of nanoparticles (Danhier, 2016). Although PEGylation improves stealth properties, repeated administration may trigger anti-PEG antibodies.

8.2 Manufacturing and Scalability Issues

Producing nanocarriers with consistent size, stability, and drug loading efficiency remains challenging. Scaling up polymeric and lipid-based nanoparticles often results in batch variability (Ventola, 2017). Regulatory agencies require stringent characterization, adding complexity to clinical approval.

8.3 Regulatory and Safety Challenges

Long-term toxicity, biodegradation kinetics, and organ accumulation remain insufficiently understood for many nanomaterials (Hare et al., 2017). Metallic nanoparticles (e.g., gold, iron oxide) raise particular concerns regarding persistence in tissues.

8.4 Economic and Logistical Barriers

High production costs, limited GMP-grade materials, and lack of standardized clinical evaluation frameworks impede commercialization. Only a few nanomedicines have reached the breast cancer market despite extensive research.

Table 7. Key Challenges Limiting Clinical Translation of Nanomedicine in Breast Cancer